# Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

> **NCT03878524** · PHASE1 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Anatomic Stage IV Breast Cancer AJCC v8
- Anemia
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Castration-Resistant Prostate Carcinoma
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Hematopoietic and Lymphoid System Neoplasm
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Breast Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Pancreatic Adenocarcinoma
- Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Primary Myelofibrosis
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Hematologic Malignancy
- Recurrent Hodgkin Lymphoma
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Recurrent Myeloproliferative Neoplasm
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Plasma Cell Myeloma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Hematologic Malignancy
- Refractory Hodgkin Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Myelodysplastic Syndrome
- Refractory Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Non-Hodgkin Lymphoma
- Refractory Plasma Cell Myeloma
- Refractory Primary Myelofibrosis
- Refractory Small Lymphocytic Lymphoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Unresectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Abiraterone
- **DRUG:** Afatinib
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Bicalutamide
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Bortezomib
- **DRUG:** Cabazitaxel
- **DRUG:** Cabozantinib
- **DRUG:** Capecitabine
- **DRUG:** Carboplatin
- **DRUG:** Celecoxib
- **DRUG:** Cobimetinib
- **DRUG:** Copanlisib
- **DRUG:** Dabrafenib
- **DRUG:** Dacomitinib
- **DRUG:** Darolutamide
- **DRUG:** Dasatinib
- **DRUG:** Doxorubicin
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT03878524
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-01
- **Primary completion:** 2020-12-10
- **Final completion:** 2020-12-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2024-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878524, "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03878524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*